

117TH CONGRESS
2D SESSION

S. 4794

To amend the Public Health Service Act with respect to opioid overdose reversal medication access, education, and co-prescribing grant programs, and for other purposes.

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 7, 2022

Ms. BALDWIN introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act with respect to opioid overdose reversal medication access, education, and co-prescribing grant programs, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Naloxone Education
5 and Access Act”.

1 **SEC. 2. OPIOID OVERDOSE REVERSAL MEDICATION AC-**
2 **CESS, EDUCATION, AND CO-PRESCRIBING**
3 **GRANT PROGRAMS.**

4 Section 545 of the Public Health Service Act (42
5 U.S.C. 290ee) is amended—

6 (1) in the section heading, by striking “**AC-**
7 **CESS AND EDUCATION**” and inserting “**ACCESS,**
8 **EDUCATION, AND CO-PRESCRIBING**”;

9 (2) in subsection (a)—

10 (A) in the subsection heading, by striking
11 “**TO STATES**”;

12 (B) in the matter preceding paragraph (1),
13 by striking “States” and inserting “eligible en-
14 tities”;

15 (C) in paragraph (1), by striking “for
16 pharmacists to dispense a drug or device ap-
17 proved or cleared” and inserting “that increase
18 access to drugs and devices approved, cleared,
19 or otherwise legally marketed”;

20 (D) by redesignating paragraphs (3) and
21 (4) as paragraphs (5) and (6), respectively;

22 (E) by inserting after paragraph (2) the
23 following:

24 “(3) encourage health care providers to co-pre-
25 scribe, as appropriate, drugs or devices approved,
26 cleared, or otherwise legally marketed under the

1 Federal Food, Drug, and Cosmetic Act for emer-
2 gency treatment of known or suspected opioid over-
3 dose;

4 “(4) support innovative community-based dis-
5 tribution programs of drugs or devices approved,
6 cleared, or otherwise legally marketed under the
7 Federal Food, Drug, and Cosmetic Act for emer-
8 gency treatment of known or suspected opioid over-
9 dose;”;

10 (F) in paragraphs (5) and (6), as so redesi-
11 gnated, by striking “approved or cleared” each
12 place it appears and inserting “approved,
13 cleared, or otherwise legally marketed”;

14 (3) in subsection (b)—

15 (A) by striking “State” and inserting “eli-
16 gible entity”; and

17 (B) by striking “approved or cleared” and
18 inserting “approved, cleared, or otherwise le-
19 gally marketed”;

20 (4) in subsection (c)—

21 (A) in the matter preceding paragraph (1),
22 by striking “States” and inserting “eligible en-
23 tities”; and

1 (B) by striking “approved or cleared” each
2 place it appears and inserting “approved,
3 cleared, or otherwise legally marketed”;

4 (5) in subsection (d)—

5 (A) in paragraph (1), by striking “A
6 State” and inserting “An eligible entity”;

7 (B) in paragraph (2), by striking “3” and
8 inserting “5”; and

9 (C) by amending paragraph (3) to read as
10 follows:

11 “(3) LIMITATION.—An eligible entity may
12 use—

13 “(A) not more than 10 percent of a grant
14 under this section for educating the public pur-
15 suant to subsection (a)(6); and

16 “(B) not less than 20 percent of a grant
17 under this section to offset cost-sharing for dis-
18 tribution and dispensing of drugs or devices ap-
19 proved, cleared, or otherwise legally marketed
20 under the Federal Food, Drug, and Cosmetic
21 Act for emergency treatment of known or sus-
22 pected opioid overdose.”;

23 (6) in subsection (e), by striking “a State” and
24 inserting “an eligible entity”;

25 (7) in subsection (f)—

1 (A) by striking “A State” and inserting
2 “An eligible entity”;

3 (B) by striking “in the State” and insert-
4 ing “in the jurisdiction of the eligible entity”;
5 and

6 (C) by striking “approved or cleared” and
7 inserting “approved, cleared, or otherwise le-
8 gally marketed”;

9 (8) by amending subsection (g) to read as fol-
10 lows:

11 “(g) DEFINITIONS.—In this section:

12 “(1) ELIGIBLE ENTITY.—The term ‘eligible en-
13 tity’ means a State, locality, Indian Tribe, Tribal or-
14 ganization, or Urban Indian organization.

15 “(2) INDIAN TRIBE.—The term ‘Indian Tribe’
16 has the meaning given the term in section 4 of the
17 Indian Self-Determination and Education Assistance
18 Act.

19 “(3) STANDING ORDER.—The term ‘standing
20 order’ means a document prepared by a person au-
21 thorized to prescribe medication that permits an-
22 other person to acquire, dispense, or administer
23 medication without a person-specific prescription.

24 “(4) TRIBAL ORGANIZATION.—The term ‘Tribal
25 organization’ has the meaning given the term in sec-

1 tion 4 of the Indian Self-Determination and Edu-
2 cation Assistance Act.

3 “(5) URBAN INDIAN ORGANIZATION.—The term
4 ‘Urban Indian organization’ has the meaning given
5 the term in section 4 of the Indian Health Care Im-
6 provement Act.”; and

7 (9) in subsection (h)(1)—

8 (A) by striking “\$5,000,000” and inserting
9 “\$10,000,000”; and

10 (B) by striking “2017 through 2019” and
11 inserting “2023 through 2027”.

○